TrialClinical cancer research : an official journal of the American Association for Cancer Research2023

Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial.

Shuchi Gulati et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.